<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806479</url>
  </required_header>
  <id_info>
    <org_study_id>15049</org_study_id>
    <nct_id>NCT02806479</nct_id>
  </id_info>
  <brief_title>Hypertrophic Cardiomyopathy Pilot Study</brief_title>
  <official_title>Pilot Observational Case-control Study of the Electrical Heterogeneity in Patients With Hypertrophic Cardiomyopathy and High Arrhythmic Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates mechanisms of arrhythmogenicity in hypertrophic cardiomyopathy, in
      comparison to patients with well-understood arrhythmogenic substrate (ischemic
      cardiomyopathy), as well as to individuals free from arrhythmogenic substrate
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-invasively reconstructed epicardial activation map</measure>
    <time_frame>within one day</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Case: Hypertrophic cardiomyopathy</arm_group_label>
    <description>HCM patients at high risk for ventricular arrhythmia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control I: Healthy</arm_group_label>
    <description>Healthy Controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control II: Post-MI with arrhythmogenic substrate</arm_group_label>
    <description>Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control III: VT/VF-free ischemic cardiomyopathy</arm_group_label>
    <description>Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational: Arrhythmogenic Substrate</intervention_name>
    <arm_group_label>Case: Hypertrophic cardiomyopathy</arm_group_label>
    <arm_group_label>Control II: Post-MI with arrhythmogenic substrate</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Case - Control study of hypertrophic cardiomyopathy patients at high risk for ventricular
        arrhythmias in comparison to three Controls groups
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed HCM

          -  Documented history of sustained ventricular tachyarrhythmia or resuscitated sudden
             cardiac arrest

          -  Maximal left ventricular wall thickness of &gt; 30mm

          -  Extensive fibrosis on cardiac MRI (&gt;15% of total myocardial volume)

          -  &gt;7.5%/5-year risk of sudden cardiac death as determined by HCM risk-SCD

        Exclusion Criteria:

          -  age &lt; 18 years

          -  Pregnancy

          -  Atrial Fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Larisa Tereshchenko</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

